Artiva Q3 2024 net loss $17.5M; cash $199.6M; AlloNK data expected H1 2025

Artiva Biotherapeutics, Inc.

2024-Q3 EPS reported -$7.16 revenue$251,000

Net loss of $17.5M for Q3 2024 vs net income of $11.3M a year ago as collaboration revenue ended.
Cash, equivalents and investments $199.6M at Sep 30, 2024; expected to fund operations through end of 2026.
Completed upsized IPO in July 2024, gross proceeds $179.0M from 14.92M shares at $12.00.
First patient dosed in AlloNK IIT for autoimmune diseases; initial Phase 1/1b and IIT data due H1 2025.
Appointed Dr. Alison Moore to Board of Directors, bringing allogeneic cell therapy manufacturing expertise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.